Int J Cancer: Study reveals EphA2-YAP pathway drives growth of stomach cancer and treatment of drug resistance
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Yes-related protein (YAP) is a transcription-assisted activator that promotes cell proliferation, stem cell maintenance and tissue balanceThe activity of YAP is regulated mainly by the Hippo pathway of serine/sucine kinase, which inhibits phosphorylated phosphorylationhere, we show that receptor tyrosine kinase (RTK) erythropoietin hepatocellular receptor A2 (EphA2) interacts with the YAP protein and phosphoritizes it, causing YAP to stabilize, nucleartransteand, and activate in stomach cancer (GC) cellsEphA2 induces chemotherapy resistance by increasing the stability of YAP and nuclear YAP proteinYap knocking can block the growth of EphA2-induced tumors in GC xenotransplant edges mouse modelsImportantly, the co-living of EphA2 and YAP is shown as co-living in clinical human GC as EphA2 and YAP, and is associated with GC recurrencetherefore, our results have established a new type of EphA2-to-YAP pathway that drives the growth, progression and resistance of GC, which will be an effective way to treat GC, especially chemotherapy-resistant GC
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
